We have previously shown that CD200High AML patients exhibited reduced Natural Killer (NK) and T cell immune responses in comparison to CD200Low patients, indicating that CD200 is a potential immunotherapeutic target in this disease. This evidence concerns the gene CD200 and acute myeloid leukemia.